Electra Therapeutics closed a $183 million Series C to fund pivotal testing of its lead monoclonal antibody ELA026 for secondary hemophagocytic lymphohistiocytosis (HLH) and to advance additional immunology programs. Investors included strategic backers such as Sanofi alongside growth investors; management said the cash enables an accelerated Phase 2/3 program and expansion into oncology indications. The financing underscores ongoing investor appetite for high‑need, narrowly defined immunology and rare‑disease targets with rapid regulatory pathways.